Sharaf Abubakar

Applications for MSK's QSURE 2025 summer #internship program are now open! This program provides undergraduate students hands-on experience in quantitative science research. Applications are due by 5pm ET on 1/18. Apply ⬇️ www.mskcc.org/departments/...

AACR Grantee Studies a Rare Form of Sarcoma Small donations to the AACR add up to big support for promising research on treatment of a sarcoma that strikes teenagers and young adults.

Small donations to the AACR had a big impact on Madelyn Espinosa-Cotton, PhD. Discover how contributions from individual donors funded the grant for her research on a rare and aggressive type of sarcoma. Read her story: www.aacr.org/about-the-aa... #GivingTuesday

Congratulations on the article. Particularly enjoyed the talk you gave at MSKCC weeks ago.

🚨Last call: The deadline to apply for the Cancer Biology or Cancer Engineering #PhD programs at MSK's Gerstner Sloan Kettering graduate school is 12/1. Don't miss the opportunity to make the next groundbreaking discovery in cancer & biomedical sciences. Apply: www.sloankettering.edu/gerstner/adm...

AACR Cancer Progress Report 2024. The Report highlights research-driven advances in cancer science and medicine. Learn more at CancerProgressReport.org

The AACR Cancer Progress Report 2024 highlights research-driven advances in cancer science and medicine. Read the Report: CancerProgressReport.org 
#CancerProgressReport

(1/2) NEW🚨: The @fda.gov has approved the drug #zanidatamab to treat advanced and metastatic #bileductcancer and other biliary tract cancers that have high levels of a protein called #HER2 and do not respond to chemotherapy.

The American Association for Cancer Research and its more than 58,000 members worldwide are advancing a scientifically bold agenda against the collection of devastating diseases we call cancer.
aacr.org
#CancerResearchSavesLives®

Senior students & recent graduates who are looking for #biomedical #research opportunities - our #MSKBridge #postbac program is now open for applications.

Deadline to apply: FEBRUARY 21, 2025.

What is Bridge about? mskcc.org/bridge
& don’t forget to check out the FAQs.

Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma - Nature The prodrug gliocidin effectively kills glioblastoma cells by targeting de novo purine synthesis, improving survival in mouse models.

A research team from MSK’s Sloan Kettering Institute and collaborators have identified a compound called gliocidin that may have the potential to improve the survival of patients with #glioblastoma – now in @natureportfolio.bsky.social #oncSKY #medSKY
Read the study: www.nature.com/articles/s41...